An observational study in Non Small Cell Lung Cancer, sponsored by Hunan Province Tumor Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.
Sponsored by Hunan Province Tumor Hospital · Observational
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
This prospective study aimed to assess its efficacy and adverse event for Checkpoint Inhibitors with or without chemotherapy in clincial practice. Several cohorts were devided including pathological type, treatment line, treatment regiems, combination strategies. Tissue samples were collected with permission of patients for TME evaluation.
6,641 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,665 are open to participants now.
This study's planned enrollment of 15,000 is above the median of 164 across 974 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Hunan Province Tumor Hospital is the lead sponsor of 75 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients did not match for the Inclusion Criteria.
Extansive Stage Small Cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
Drug: Immune checkpoint inhibitor
Limit Stage Small Celll Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors .
Drug: Immune checkpoint inhibitor
Small Celll Lung Cancer who progressed from first line treatment and received subsequential Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Metastastic Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Metastastic Non-small cell Lung Cancer who progressed from first line treatment and received subsequential Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Resectable Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Unresectable Non-small cell Lung Cancer treated with first line Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Non-small cell Lung Cancer received neoadjuvent or adjuvent Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Cohort I, Non-small cell Lung Cancer with EGFR, ALK and ROS1 sensitive mutation who received Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Non-small cell Lung Cancer with other oncogenic mutation including RET, BRAF etc who received Chemotherapy with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Non-small cell Lung Cancer received Chemotherapy plus bevacizumab with or without Checkpoint Inhibitors.
Drug: Immune checkpoint inhibitor
Non-small cell Lung Cancer who enrolled in clinical trials.
Drug: Immune checkpoint inhibitor
Chemotherapy follow the guild line.
Also known as: Chemotherapy
Progression-free survival (PFS)
To assess progression-free survival of patients treated by different treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as first dose to first documented disease progression assessed by investigator or death due to any cause
Time frame: Time from first subject dose to study completion, or up to 36 month
Overall survival (OS)
To assess overall survival, define as first dose to the death of the subject due to any cause
Time frame: Time from first subject dose to study completion, or up to 36 months.
Objective Response Rate (ORR)
To assess ICI and TKIs overall response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Time frame: Time from first subject dose to study completion, or up to 36 months.
Duration of Response (DOR)
To assess duration of response for subjects with CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator , defined as the time from the first documented CR or PR to disease progression or death
Time frame: Time from first subject dose to study completion, or up to 36 month
Adverse events (AEs) according to CTCAE 5.0
Number of participants with adverse events (AEs) according to CTCAE 5.0
Time frame: From first dose until 28 days after the last dose, up to 24 month
Patient reported outcome
Patient reported outcomes (PROs): A report that directly reflects a patient's assessment of their own health status.
Time frame: Time from first subject dose to study completion, or up to 36 months.
Started Oct 2021 (actual). Primary completion is estimated for Sep 2026, 59 months after the start.
Of 312 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 155. This study's planned 59 months is close to that.
Counting every sponsor, half of 440 studies reached it within 56 months; a quarter within 36 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Hunan Province Tumor Hospital